Company overview

Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. The company is developing RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. Community Guidelines: https://rb.gy/07ltg3
Founded in 2007
Waltham, Massachusetts, USA
467 employees (24 in marketing)
70% recommend to a friend
64% positive business outlook

Salaries

Typical salary range

$217,500 – $266,000

/ yr

Help build salary transparency at Ardelyx, Inc.

Share your compensation anonymously to see full data.

Contribute

People

Hiring activity

Open marketing jobs over time

1 open now

Headcount trend

Company growth over the last 12 months

Headcount +20.5% year over year

Funding

Total funding

$557.7M

Last raise

$20M

Post IPO Debt, 4 years ago

Funding history

Jun 2022

Post IPO Debt Ardelyx · $20M

Feb 2022

Post IPO Debt Ardelyx · $27.5M

Dec 2019

Post IPO Equity Ardelyx · $125M

May 2018

Post IPO Debt Ardelyx · $50M

Jul 2016

Post IPO Equity Ardelyx · $110M

Jan 2016

Post IPO Equity Ardelyx · $86.3M

Audience

Monthly website visitors
11.9K
Month over month-25.6%
Quarter over quarter-21.5%
Top sourceDirect (42.5%)
Ad budget per month$0.0
Average search rank48.7
Traffic source mix
Direct
42.5%
Search
42.3%
Social
8%
Referral
5.8%
Paid referral
1.2%

LinkedIn followers

Follower count and growth

Total followers

25.5K

12-mo growth

+41.9%

Monthly growth

+6.3%

News

Links